Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 7,093 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, pamidronate disodium, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
4
States / cities
Chicago, Illinois • Hackensack, New Jersey • Cleveland, Ohio + 1 more
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Conditions
Solid Tumor, Adult
Interventions
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
No Longer Available No phase listed Expanded access

Expanded Access to ANG1005 for Individual Patients

NCT02755987
Conditions
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
Interventions
ANG1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older · Female only
U.S. locations
2
States / cities
Orange, California • San Antonio, Texas
Conditions
Menopause, Postmenopausal Bone Loss, Breast Cancer
Interventions
Tibolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Vinorelbine, Trastuzumab Emtansine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Conditions
HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1259
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
Conditions
Breast Cancer
Interventions
Couples MBSR, Individual MBSR
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Breast Cancer, Cervical Cancer
Interventions
Unidas por Vida y Salud prevention program
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer Female, Gynecologic Cancer
Interventions
rTMS
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
Interventions
entinostat, exemestane, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Greenbrae, California • La Jolla, California • Aurora, Colorado + 20 more
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Conditions
Breast Cancer, Mastectomy, Perfusion; Complications, Hemostasis
Interventions
PlasmaBlade 3.0S
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Breast Neoplasms
Interventions
High-Dose Chemo with Autologous BMT
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2002
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Phase 2 Interventional Accepts healthy volunteers

Tamoxifen-MRI Study

NCT00295100
Conditions
Breast Cancer
Interventions
Tamoxifen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 45 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Nivolumab, Talimogene Laherparepvec
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Breast Cancer
Interventions
E75 + GM-CSF vaccine
Biological
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
2
States / cities
Bethesda, Maryland • Windber, Pennsylvania
Recruiting Phase 2 Interventional

Sacituzumab Govitecan In TNBC

NCT04230109
Conditions
Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
Sacituzumab Govitecan, Pembrolizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
Conditions
Metastatic Breast Cancer
Interventions
docetaxel, capecitabine
Drug
Lead sponsor
Cancer Research Network
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Plantation, Florida
Conditions
Breast Cancer
Interventions
adjuvant therapy, 3-dimensional conformal radiation therapy, brachytherapy
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
4
States / cities
Cleveland, Ohio
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
3
States / cities
Cleveland, Ohio • Mentor, Ohio • Orange, Ohio
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

NCT06395506
Conditions
Breast Cancer, Breast Cancer Female, Muscle Weakness
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Galveston, Texas